TY - JOUR
T1 - Symmetric dimethylarginine is altered in patients after myocardial infarction and predicts adverse outcomes
AU - Gąsecka, Aleksandra
AU - Szwed, Piotr
AU - Jasińska, Karolina
AU - Fidali, Oliwia
AU - Kłębukowska, Aleksandra
AU - Eyileten, Ceren
AU - Postula, Marek
AU - Szarpak, Łukasz
AU - Mazurek, Tomasz
AU - Opolski, Grzegorz
AU - Filipiak, Krzysztof J.
AU - Ufnal, Marcin
N1 - Funding Information: National Science Centre, Poland, grant no: 2020/37/B/ NZ5/00366. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Funding Information: A. Gasecka, C. Eyileten, M. Postu?a and K. J. Filipiak acknowledge the International and Intercontinental Cardiovascular and Cardiometabolic Research Team (I-COMET). National Science Centre, Poland, grant no: 2020/37/B/ NZ5/00366. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Publisher Copyright: © 2021 Gąsecka et al. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Purpose: Acute myocardial infarction (AMI) is the leading cause of morbidity and mortality worldwide. Damage to the endothelium is the earliest event in atherothrombosis, including AMI. Nitric oxide (NO), an endothelium-derived compound, protects the vasculature from damage. This study evaluated whether an association exists between plasma concentration of endogenous NO-related pathway metabolites linked to AMI and major adverse cardiovascular events (MACE) after AMI. Methods: We compared plasma concentrations of NO-related pathway metabolites in patients after AMI (n=60) and healthy controls (n=27) and investigated the prognostic value of these metabolites for post-AMI MACE development over a median of 3.5-years. In search of biomarkers, we compared plasma concentrations of dimethylarginines (ADMA, SDMA), citrulline, arginine and ornithine using ultra performance liquid chromatograph coupled with a mass spectrometer. Results: Patients after AMI had higher concentrations of dimethylarginines, compared to controls (p=0.0068, p<0.0001, respectively). Conversely, the concentration of citrulline was lower in the AMI group (p=0.0006). The concentration of SDMA was higher in patients who developed MACE than in those who did not (p=0.015). SDMA was the only independent predictor of MACE in multivariate analysis (p=0.023). There was an intermediate, negative correlation between plasma SDMA level and platelet reactivity (r=−0.33, p=0.02). Conclusion: Plasma concentration of dimethylarginines differs between patients with AMI and healthy volunteers. The study’s novel finding is that SDMA is an independent predictor of MACE during a 3.5 year follow-up period after AMI.
AB - Purpose: Acute myocardial infarction (AMI) is the leading cause of morbidity and mortality worldwide. Damage to the endothelium is the earliest event in atherothrombosis, including AMI. Nitric oxide (NO), an endothelium-derived compound, protects the vasculature from damage. This study evaluated whether an association exists between plasma concentration of endogenous NO-related pathway metabolites linked to AMI and major adverse cardiovascular events (MACE) after AMI. Methods: We compared plasma concentrations of NO-related pathway metabolites in patients after AMI (n=60) and healthy controls (n=27) and investigated the prognostic value of these metabolites for post-AMI MACE development over a median of 3.5-years. In search of biomarkers, we compared plasma concentrations of dimethylarginines (ADMA, SDMA), citrulline, arginine and ornithine using ultra performance liquid chromatograph coupled with a mass spectrometer. Results: Patients after AMI had higher concentrations of dimethylarginines, compared to controls (p=0.0068, p<0.0001, respectively). Conversely, the concentration of citrulline was lower in the AMI group (p=0.0006). The concentration of SDMA was higher in patients who developed MACE than in those who did not (p=0.015). SDMA was the only independent predictor of MACE in multivariate analysis (p=0.023). There was an intermediate, negative correlation between plasma SDMA level and platelet reactivity (r=−0.33, p=0.02). Conclusion: Plasma concentration of dimethylarginines differs between patients with AMI and healthy volunteers. The study’s novel finding is that SDMA is an independent predictor of MACE during a 3.5 year follow-up period after AMI.
KW - Acute myocardial infarction
KW - L-arginine
KW - Major adverse cardiovascular events
KW - Nitric oxide
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85113141053&partnerID=8YFLogxK
U2 - https://doi.org/10.2147/JIR.S316078
DO - https://doi.org/10.2147/JIR.S316078
M3 - Article
C2 - 34408463
SN - 1178-7031
VL - 14
SP - 3797
EP - 3808
JO - Journal of Inflammation Research
JF - Journal of Inflammation Research
ER -